Annex H
FORM OF REGISTRATION RIGHTS AGREEMENT
This Registration Rights Agreement (this “Agreement”) is made and entered into as of [•], 2026, among Remix Therapeutics, Inc., a Delaware corporation (“Remix”), Passage Bio, Inc., a
Delaware corporation (“Passage”), and each of the several investors signatory hereto.
WHEREAS, Remix and Passage are party to that certain Amended and
Restated Agreement and Plan of Merger by and among Remix, Peregrine Merger Sub, Inc., Peregrine Merger Sub II, LLC and Passage, dated as of [•], 2026 (the “Merger Agreement”),
pursuant to which the Company will become a wholly-owned subsidiary of Passage (the “Merger”);
WHEREAS, following the Effective Time (as defined in the Merger
Agreement), Passage will change its name to Remix Therapeutics, Inc. (“TopCo”);
WHEREAS, the Company and certain investors (the “Purchasers”) are parties to an Amended and Restated Subscription Agreement, dated as of [•], 2026 (the “Purchase Agreement”),
pursuant to which such Purchasers, severally and not jointly, are purchasing, prior to the Initial Effective Time, (A) shares of common stock of Remix (the “Purchased Shares”)
and/or (B) pre-funded warrants to purchase shares of common stock of Remix (“Pre-Funded Warrants” and together with the Purchased Shares, the “Purchased Securities” and the shares of common stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”, which shares shall be
common stock of Remix prior to the Effective Time and Common Stock after the Effective Time);
WHEREAS, pursuant to that certain Convertible Promissory Note Purchase
Agreement, dated as of June 24, 2026 (the “Bridge Note Purchase Agreement”), Remix has issued $[•] aggregate principal amount of convertible promissory notes (the “Bridge Notes”) to certain lenders (the “Bridge Note Lenders”);
WHEREAS, pursuant to that certain Convertible Promissory Note Purchase
Agreement, dated as of November 14, 2025, as amended by the Omnibus Amendment No. 1 to Convertible Promissory Note and Warrant Purchase Agreement and Notes, dated as of June 24, 2026 (as amended, the “2025 Note Purchase Agreement”), Remix has issued $29,988,211.99 aggregate principal amount of convertible promissory notes (the “2025 Notes”) to
certain lenders (the “2025 Notes Lenders” and together with the Bridge Note Lenders, the “Lenders”);
WHEREAS, the Bridge Note Purchase Agreement and the 2025 Note Purchase
Agreement provide that if, prior to the maturity date of the Bridge Notes and the 2025 Notes, as applicable, a PIPE Offering (as defined in each of the Bridge Note Purchase Agreement and the 2025 Note Purchase Agreement) is consummated,
then the outstanding amount under each Bridge Note and each 2025 Note will be converted automatically and concurrently into a number of shares of common stock of Remix or exchanged for Pre-Funded Warrants at the election of the holder of
the Bridge Notes (collectively, the “Conversion Securities”);
WHEREAS, at the Initial Effective Time by virtue of the Merger, the
shares of common stock of Remix shall be automatically converted into the right to receive a number of shares of common stock, par value $0.0001 per share, of TopCo (the “Common Stock”),
in accordance with Section 2.4(d) of the Merger Agreement;
WHEREAS, at the Effective Time by virtue of the Merger, the Pre-Funded
Warrants shall be assumed by TopCo and such Pre-Funded Warrants shall become exercisable for shares of Common Stock of TopCo in accordance with the terms set forth in the Merger Agreement; and
WHEREAS, in connection with the consummation of the transactions
contemplated by the Purchase Agreement, and pursuant to the terms of the Purchase Agreement, the parties desire to enter into this Agreement in order to grant certain rights to the Purchasers and the Lenders as set forth below.